Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 8, 2007 - Issue 14
Submit an article Journal homepage
205
Views
7
CrossRef citations to date
0
Altmetric
Review

Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era

Hisham Ziglam Consultant in Infectious Diseases and Acute Medicine, Manchester Royal Infirmary, Platt Rehab II, Purple Zone, Oxford Road, Manchester, M13 3WL, UK +44 161 276 6640;+44 161 276 3541;[email protected]
, DIC MSc MD FRCP
Pages 2279-2292 | Published online: 10 Oct 2007

Bibliography

  • EDMOND MB, WALLACE SE, MCCLISH DK et al.: Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. (1999) 29(2):239-244.
  • NATHWANI D, BARLOW GD, AJDUKIEWICZ K et al.: Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy. J. Antimicrob. Chemother. (2003) 51(2):391-396.
  • BIEDENBACH DJ, MOET GJ, JONES RN: Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997 – 2002). Diagn. Microbiol. Infect. Dis. (2004) 50(1):59-69.
  • DIEKEMA DJ, PFALLER MA, SCHMITZ FJ et al.: Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997 – 1999. Clin. Infect. Dis. (2001) 32(Suppl. 2):S114-S132.
  • BARRETT JF: Recent developments in glycopeptide antibacterials. Curr. Opin. Investig. Drugs (2005) 6(8):781-790.
  • MENICHETTI F: Current and emerging serious Gram-positive infections. Clin. Microbiol. Infect. (2005) 11(Suppl. 3):22-28.
  • PLOWMAN R: The socioeconomic burden of hospital acquired infection. Euro Surveill. (2000) 5(4):49-50.
  • TALLY FP, ZECKEL M, WASILEWSKI MM et al.: Daptomycin: a novel agent for Gram-positive infections. Expert Opin. Investig. Drugs (1999) 8(8):1223-1238.
  • CARPENTER CF, CHAMBERS HF: Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin. Infect. Dis. (2004) 38(7):994-1000.
  • SILVERMAN JA, PERLMUTTER NG, SHAPIRO HM: Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. (2003) 47(8):2538-2544.
  • LAPLANTE KL, RYBAK MJ: Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. (2004) 48(12):4665-4672.
  • CLSI: Clinical and Laboratory Standards Institute. M7-A7, methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In: Approved Standard, 7th Edition, Wayne, PA7 CLSI (2006).
  • CLSI: Clinical and Laboratory Standards Institute. M100-S16, Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement. Wayne, PA7 CLSI (2006).
  • PFALLER MA, SADER HS, JONES RN: Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002 – 2005). Diagn. Microbiol. Infect. Dis. (2007)
  • SADER HS, STREIT JM, FRITSCHE TR, JONES RN: Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002 – 2004). Clin. Microbiol. Infect. (2006) 12(9):844-852.
  • WOODFORD N: Novel agents for the treatment of resistant Gram-positive infections. Expert Opin. Investig. Drugs (2003) 12(2):117-137.
  • RAAD I, HANNA H, JIANG Y et al.: Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother. (2007) 51(5):1656-1660.
  • GREEN MR, ANASETTI C, SANDIN RL, ROLFE NE, GREENE JN: Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J. Oncol. Pharm. Pract. (2006) 12(3):179-181.
  • LEWIS JS II, OWENS A, CADENA J et al.: Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob. Agents Chemother. (2005) 49(4):1664-1665.
  • MARTY FM, YEH WW, WENNERSTEN CB et al.: Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J. Clin. Microbiol. (2006) 44(2):595-597.
  • SKIEST DJ: Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J. Clin. Microbiol. (2006) 44(2):655-656.
  • HAYDEN MK, REZAI K, HAYES RA et al.: Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. (2005) 43(10):5285-5287.
  • MANGILI A, BICA I, SNYDMAN DR, HAMER DH: Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. (2005) 40(7):1058-1060.
  • SILVERMAN JA, OLIVER N, ANDREW T, LI T: Resistance studies with daptomycin. Antimicrob. Agents Chemother. (2001) 45(6):1799-1802.
  • CUI L, TOMINAGA E, NEOH HM, HIRAMATSU K: Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. (2006) 50(3):1079-1082.
  • AKINS RL, RYBAK MJ: In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob. Agents Chemother. (2000) 44(7):1925-1929.
  • CREDITO K, LIN G, APPELBAUM PC: Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus by time-kill methodology. Antimicrob. Agents Chemother. (2007).
  • RAND KH, HOUCK H: Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J. Antimicrob. Chemother. (2004) 53(3):530-532.
  • RAND KH, HOUCK HJ: Synergy of daptomycin with oxacillin and other β-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2004) 48(8):2871-2875.
  • DVORCHIK BH, BRAZIER D, DEBRUIN MF, ARBEIT RD: Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. (2003) 47(4):1318-1323.
  • LEE BL, SACHDEVA M, CHAMBERS HF: Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob. Agents Chemother. (1991) 35(12):2505-2508.
  • TALLY FP, DEBRUIN MF: Development of daptomycin for gram-positive infections. J. Antimicrob. Chemother. (2000) 46(4):523-526.
  • TEDESCO KL, RYBAK MJ: Daptomycin. Pharmacotherapy (2004) 24(1):41-57.
  • FUCHS PC, BARRY AL, BROWN SD: In vitro bactericidal activity of daptomycin against staphylococci. J. Antimicrob. Chemother. (2002) 49(3):467-470.
  • RYBAK MJ, HERSHBERGER E, MOLDOVAN T, GRUCZ RG: In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. (2000) 44(4):1062-1066.
  • BUSH LM, BOSCIA JA, WENDELER M, PITSAKIS PG, KAYE D: In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. (1989) 33(8):1198-1200.
  • HANBERGER H, NILSSON LE, MALLER R, ISAKSSON B: Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob. Agents Chemother. (1991) 35(9):1710-1716.
  • PETTI CA, FOWLER VG JR: Staphylococcus aureus bacteremia and endocarditis. Cardiol. Clin. (2003) 21(2):VII219-233.
  • FOWLER VG Jr, KONG LK, COREY GR et al.: Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J. Infect. Dis. (1999) 179(5):1157-1161.
  • WOODS CW, CHENG AC, FOWLER VG Jr et al.: Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis. (2004) 38(8):1188-1191.
  • CANTONI L, GLAUSER MP, BILLE J: Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob. Agents Chemother. (1990) 34(12):2348-2353.
  • CARON F, KITZIS MD, GUTMANN L et al.: Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob. Agents Chemother. (1992) 36(12):2611-2616.
  • FOWLER VG Jr, BOUCHER HW, COREY GR et al.: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. (2006) 355(7):653-665.
  • SEGRETI JA, CRANK CW, FINNEY MS: Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy (2006) 26(3):347-352.
  • POUTSIAKA DD, SKIFFINGTON S, MILLER KB, HADLEY S, SNYDMAN DR: Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J. Infect. (2006) 54(6):567-571.
  • ARBEIT RD, MAKI D, TALLY FP, CAMPANARO E, EISENSTEIN BI: The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. (2004) 38(12):1673-1681.
  • PHARMACEUTICALS C: Data on file. Lexington, MA (2003).
  • SILVERMAN JA, MORTIN LI, VANPRAAGH AD, LI T, ALDER J: Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. (2005) 191(12):2149-2152.
  • NABER KG EB, TALLY, FRANCIS P: Daptomycin versus ciprofloxacin in the treatment of complicated urinary tract infection due to gram-positive bacteria. Infect. Dis. Clin. Pract. (2004) 12(6):322-327.
  • CUBIST PHARMACEUTICALS: Data on file. In: Lexington, MA (2003).
  • HAYES D Jr, ANSTEAD MI, KUHN RJ: Eosinophilic pneumonia induced by daptomycin. J. Infect. (2007) 54(4):E211-E213.
  • BERGERON J, AMMIRATI M, DANLEY D et al.: Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob. Agents Chemother. (1996) 40(9):2226-2228.
  • FRITSCHE TR, SADER HS, STILWELL MG, DOWZICKY MJ, JONES RN: Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000 – 2004). Diagn. Microbiol. Infect. Dis. (2005) 52(3):195-201.
  • FRITSCHE TR, SADER HS, STILWELL MG, DOWZICKY MJ, JONES RN: Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. (2005) 52(3):187-193.
  • SADER HS, JONES RN, STILWELL MG, DOWZICKY MJ, FRITSCHE TR: Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn. Microbiol. Infect. Dis. (2005) 52(3):181-186.
  • HOBAN DJ, BOUCHILLON SK, JOHNSON BM, JOHNSON JL, DOWZICKY MJ: In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program 2004). Diagn. Microbiol. Infect. Dis. (2005) 52(3):215-227.
  • SADER HS, JONES RN, DOWZICKY MJ, FRITSCHE TR: Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn. Microbiol. Infect. Dis. (2005) 52(3):203-208.
  • BRADFORD PA, WEAVER-SANDS DT, PETERSEN PJ: In vitro activity of tigecycline against isolates from patients enrolled in Phase III clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. (2005) 41(Suppl. 5):S315-S332.
  • BOUCHILLON SK, HOBAN DJ, JOHNSON BM et al.: In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program 2004). Diagn. Microbiol. Infect. Dis. (2005) 52(3):173-179.
  • BIEDENBACH DJ, BEACH ML, JONES RN: In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases. Diagn. Microbiol. Infect. Dis. (2001) 40(4):173-177.
  • HOPE R, WARNER M, POTZ NA et al.: Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England. J. Antimicrob. Chemother. (2006) 58(6):1312-1314.
  • SCHEETZ MH, QI C, WARREN JR et al.: In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. (2007) 51(5):1621-1626.
  • WALLACE RJ Jr, BROWN-ELLIOTT BA, CRIST CJ, MANN L, WILSON RW: Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob. Agents Chemother. (2002) 46(10):3164-3167.
  • MURALIDHARAN G, MICALIZZI M, SPETH J, RAIBLE D, TROY S: Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. (2005) 49(1):220-229.
  • HOFFMAN H HW, DEMAIO RA, JORDAN J, KANTROWITZ D, HARPER J, SPETH J: Metabolic disposition of [14C]tigecycline in human volunteers following intravenous infusion In: 2004 AAPS Annual Meeting and Exposition, American Association of Pharmaceutical Scientists. Baltimore, USA (7 – 11 November 2004).
  • PHILADELPHIA PWP: Tigecycline Phamacokinetics (data on file) (2006).
  • CHIN TF, LACH JL: Drug diffusion and bioavailability: tetracycline metallic chelation. Am. J. Hosp. Pharm. (1975) 32(6):625-629.
  • SUN HK, ONG CT, UMER A et al.: Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob. Agents Chemother. (2005) 49(4):1629-1632.
  • TROY SM MG, MICALIZZI M: The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. (Chicago) Washington, DC: American Society for Microbiology (2003).
  • FOMIN P BM, GRADAUSKAS AEAL: Tigecycline is efficaciousin the treatment of complicated intra-abdominal infections. Int. J. Surg. (2005) 3:35-47.
  • OLIVA ME, REKHA A, YELLIN A et al.: A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; Clinical Trials.gov Identifier: NCT00081744]. BMC Infect. Dis. (2005) 5:88.
  • BABINCHAK T, ELLIS-GROSSE E, DARTOIS N, ROSE GM, LOH E: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. (2005) 41(Suppl. 5):S354-S367.
  • POSTIER RG, GREEN SL, KLEIN SR, ELLIS-GROSSE EJ, LOH E: Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin. Ther. (2004) 26(5):704-714.
  • SACCHIDANAND S, PENN RL, EMBIL JM et al.: Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a Phase III, randomized, double-blind trial. Int. J. Infect. Dis. (2005) 9(5):251-261.
  • BREEDT J, TERAS J, GARDOVSKIS J et al.: Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind Phase III comparison study with vancomycin-aztreonam. Antimicrob. Agents Chemother. (2005) 49(11):4658-4666.
  • ELLIS-GROSSE EJ, BABINCHAK T, DARTOIS N, ROSE G, LOH E: The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase III comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. (2005) 41(Suppl. 5):S341-S353.
  • MURALIDHARAN G, FRUNCILLO RJ, MICALIZZI M, RAIBLE DG, TROY SM: Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob. Agents Chemother. (2005) 49(4):1656-1659.
  • MEAGHER AK, AMBROSE PG, GRASELA TH, ELLIS-GROSSE EJ: The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis. (2005) 41(Suppl. 5):S333-S340.
  • WYETH PHARMACEUTICS: Tygacil (Tigecycline) for injection. Wyeth Pharmaceuticals, Inc., Philadelphia, PA (2006).
  • NATHWANI D: Economic impact and formulary positioning of linezolid: a new anti-Gram-positive antimicrobial. J. Hosp. Infect. (2001) 49(Suppl. A):S33-S41.
  • JOHNSON AP, MUSHTAQ S, WARNER M, LIVERMORE DM: Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Int. J. Antimicrob. Agents (2004) 24(4):315-319.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.